Cardiometabolic disease risk in metabolically healthy and unhealthy obesity: Stability of metabolic health status in adults

Obesity

Volumn 24, Issue 2, 2016, Pages 516-525

  Guo, Fangjian ^a   Garvey, W Timothy ^b,c  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LIPID; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HAZARD RATIO; HUMAN; ISCHEMIC HEART DISEASE; LEAN BODY WEIGHT; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLISM; MORTALITY; OBESITY; RISK ASSESSMENT; BLOOD; COMPLICATION; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; HEALTH STATUS; METABOLICALLY BENIGN OBESITY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STROKE; YOUNG ADULT;

ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HUMANS; LIPIDS; MALE; OBESITY; OBESITY, METABOLICALLY BENIGN; OVERWEIGHT; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STROKE; YOUNG ADULT;

EID: 84956575765     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.21344     Document Type: Article

References (35)

1. Hu FB.; Obesity and mortality: watch your waist, not just your weight. Arch Intern Med 2007; 167: 875-876.
2. Flegal KM, Carroll MD, Kit BK, Ogden CL.; Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307: 491-497.
3. Finucane MM, Stevens GA, Cowan MJ, et al.; National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011; 377: 557-567.
4. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the Evidence Report. Obes Res 1998; 6 (Suppl): 51S-209S.
5. Lara-Castro C, Garvey WT.; Diet, insulin resistance, and obesity: zoning in on data for Atkins dieters living in South Beach. J Clin Endocrinol Metab 2004; 89: 4197-4205.
6. Liao Y, Kwon S, Shaughnessy S, et al.; Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 2004; 27: 978-983.
7. Bogardus C, Lillioja S.; Pima Indians as a model to study the genetics of NIDDM. J Cell Biochem 1992; 48: 337-343.
8. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G.; Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 1997; 100: 1166-1173.
9. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ.; Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996; 45: 633-638.
10. Guo F, Moellering DR, Garvey WT.; The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity. Obesity (Silver Spring) 2014; 22: 110-118.
11. Stefan N, Kantartzis K, Machann J, et al.; Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008; 168: 1609-1616.
12. Wildman RP, Muntner P, Reynolds K, et al.; The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 2008; 168: 1617-1624.
13. Kip KE, Marroquin OC, Kelley DE, et al.; Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Circulation 2004; 109: 706-713.
14. Meigs JB, Wilson PW, Fox CS, et al.; Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006; 91: 2906-2912.
15. Yusuf S, Hawken S, Ounpuu S, et al.; Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640-1649.
16. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB.; Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066-3072.
17. Arnlov J, Ingelsson E, Sundstrom J, Lind L.; Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 2010; 121: 230-236.
18. Thomsen M, Nordestgaard BG.; Myocardial infarction and ischemic heart disease in overweight and obesity with and without metabolic syndrome. JAMA Intern Med 2014; 174: 15-22.
19. Aung K, Lorenzo C, Hinojosa MA, Haffner SM.; Risk of developing diabetes and cardiovascular disease in metabolically unhealthy normal-weight and metabolically healthy obese individuals. J Clin Endocrinol Metab 2014; 99: 462-468.
20. Appleton SL, Seaborn CJ, Visvanathan R, et al.; Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care 2013; 36: 2388-2394.
21. Jung HS, Chang Y, Eun Yun K, et al.; Impact of body mass index, metabolic health and weight change on incident diabetes in a Korean population. Obesity (Silver Spring) 2014; 22: 1880-1887.
22. Chang Y, Ryu S, Suh BS, Yun KE, Kim CW, Cho SI.; Impact of BMI on the incidence of metabolic abnormalities in metabolically healthy men. Int J Obes (Lond) 2012; 36: 1187-1194.
23. Twig G, Afek A, Derazne E, et al.; Diabetes risk among overweight and obese metabolically healthy young adults. Diabetes Care 2014; 37: 2989-2995.
24. Jung CH, Lee MJ, Kang YM, et al.; The risk of incident type 2 diabetes in a Korean metabolically healthy obese population: the role of systemic inflammation. J Clin Endocrinol Metab 2015; 100: 934-941.
25. Lloyd-Jones DM, Hong Y, Labarthe D, et al.; Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic impact goal through 2020 and beyond. Circulation 2010; 121: 586-613.
26. Expert Panel on Detection Evaluation, Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
27. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 1989; 129: 687-702.
28. Friedman GD, Cutter GR, Donahue RP, et al.; CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988; 41: 1105-1116.
29. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA.; Evaluating the yield of medical tests. JAMA 1982; 247: 2543-2546.
30. Harrell FE Jr, Lee KL, Mark DB.; Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.
31. Garvey WT, Garber AJ, Mechanick JI, et al.; American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract 2014; 20: 977-989.
32. Garvey WT.; New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approach. Endocr Pract 2013; 19: 864-874.
33. Karelis AD, Messier V, Brochu M, Rabasa-Lhoret R.; Metabolically healthy but obese women: effect of an energy-restricted diet. Diabetologia 2008; 51: 1752-1754.
34. Janiszewski PM, Ross R.; Effects of weight loss among metabolically healthy obese men and women. Diabetes Care 2010; 33: 1957-1959.
35. Kantartzis K, Machann J, Schick F, et al.; Effects of a lifestyle intervention in metabolically benign and malign obesity. Diabetologia 2011; 54: 864-868.